CanSino Biologics
688185.SH, 06185.HKTianjin, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
A leading Chinese vaccine developer leveraging adenovirus vector technology to create innovative vaccines for global infectious disease prevention.
Infectious Disease
Technology Platform
Core platform is a recombinant adenovirus type 5 (Ad5) vector for vaccine delivery, complemented by polysaccharide conjugate technology (CRM197/TT carriers) and an emerging mRNA platform for influenza.
Opportunities
Significant growth opportunities lie in the international expansion of its marketed conjugate vaccines (Menhycia, iPneucia), lifecycle management through new indications and formulations (e.g., inhaled COVID-19 vaccine), and the advancement of its high-value pipeline candidates like the shingles and TB vaccines.
Risk Factors
Key risks include intense competition in core vaccine markets (meningococcal, pneumococcal), potential volatility in COVID-19 vaccine demand, execution challenges in global commercialization, and regulatory hurdles for international approvals.
Competitive Landscape
Competes directly with global vaccine leaders (GSK, Pfizer, Sanofi) and Chinese peers (Walvax, Zhifei) in conjugate and viral vector vaccines; differentiation is driven by its adenovirus platform, inhaled delivery, and a broad pipeline targeting combination vaccines.